In clinical practice, adverse drug events are often not documented in medical records, and not communicated between care providers and across healthcare sectors electronically. Our health care system currently relies heavily on patients and families to communicate adverse drug event information among their care providers. If adverse drug event information is shared directly between health care providers, it is largely communicated using paper, fax or phone. As a result, information often falls through the cracks, and care providers may unintentionally re-expose patients to culprit medications; medications that previously caused clinically significant adverse drug events or were previously…
The FAERS Public Dashboard is a highly interactive web-based tool that will allow for the querying of FAERS data in a user friendly fashion. The intention of this tool is to expand access of FAERS data to the general public to search for information related to human adverse events reported to the FDA by the pharmaceutical industry, healthcare providers and consumers.
MedWatch, the FDA’s medical product safety reporting program for health professionals, patients and consumers.
Drugs ushered through the FDA's accelerated approval process were among those that had higher rates of safety interventions. These approvals typically rely on surrogate endpoints, meaning that researchers measured something other than survival, such as tumor size, to determine whether the drugs worked.
People who have faced debilitating side effects say we need better warnings on drugs. The FDA hasn’t been enthusiastic.
It’s no secret that the many side effects caused by medicines do not get reported to the Food and Drug Administration, but a new report suggests the magnitude of underreporting is far greater than imagined.
An Adverse Drug Event (ADE) is “Harm caused by appropriate or
inappropriate use of a drug whereas adverse drug reactions are a subset of
these events, where harm is directly caused by a drug under appropriate use
(i.e. at normal doses). Adverse drug events may include cases of provider
error, non-adherence, or incorrect dosages.
The complexity of using EMRs and the risk of adverse drug events (ADE) globally can make it even harder to deliver the best patient care.
The problem is getting worse as patients today are presenting with ever-increasing degrees of complexity, co-morbidities, and medication regimes.
The ADE Action Plan identifies efforts to date to measure and prevent ADEs, and promote medication
safety. In addition, this plan outlines future opportunities to advance patient safety with regard to the
prevention of adverse drug events among three primary drug classes: anticoagulants, diabetes agents,
Older women are at higher risk than older men of experiencing adverse reactions to drugs prescribed by their family doctor, and older patients taking more than 10 medicines are at higher risk than those taking fewer, according to a study.
An adverse drug event (ADE), according to the Office of Disease Prevention and Health Promotion, is “an injury resulting from medical intervention related to a drug. This includes medication errors, adverse drug reactions, allergic reactions, and overdoses.”
Adverse drug event (ADE) is an umbrella term that refers to any type of unexpected, potentially harmful event that happens after you take a medication, whether it be during appropriate or inappropriate circumstances.
Adverse drug events, the harmful and unintended consequences of medication use, are a leading cause of unplanned hospital admissions, and rank between the 4th and 6th cause of death in North America.
Working together to prevent adverse drug events. ActionADE is a research project focused on preventing the "adverse drug events" (ADEs) that happen when medications have harmful and unintended consequences. The ActionADE project is part of our larger Adverse Drug Event Research Program.
Although antibiotics are good drugs for certain types of infections, they are also one of the types of medicines that cause the most emergency visits for adverse drug events.